Last reviewed · How we verify
M-M-RvaxPro vaccine
M-M-RvaxPro is a recombinant measles and mumps vaccine that stimulates immune responses against measles and mumps viruses through live attenuated viral antigens.
M-M-RvaxPro is a recombinant measles and mumps vaccine that stimulates immune responses against measles and mumps viruses through live attenuated viral antigens. Used for Prevention of measles, Prevention of mumps.
At a glance
| Generic name | M-M-RvaxPro vaccine |
|---|---|
| Also known as | M-M-RVAX-PRO® |
| Sponsor | Sanofi |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains live attenuated (weakened) strains of measles and mumps viruses that replicate in vaccinated individuals, triggering both humoral (antibody) and cellular immune responses. This generates protective immunity against natural infection with wild-type measles and mumps viruses. The recombinant formulation may incorporate genetic modifications to enhance immunogenicity or safety profile compared to conventional live attenuated vaccines.
Approved indications
- Prevention of measles
- Prevention of mumps
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Rash
- Parotitis
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |